Calcitonin is indicated for use in the treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable, in the treatment of hypercalcemia, and in the treatment of postmenopausal osteoporosis when alternative treatments are not suitable. It is also used in emergencies when serum calcium levels must be quickly decreased until the underlying condition is identified. Calcitonin can be used in patients with azotemia and cases where intravenous (IV) fluids would be contraindicated due to limited cardiac reserves. It has also been used in the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause with low bone mass who refuse or don’t tolerate estrogens, or in whom estrogens are not an option.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.